Australia's largest stock trading and investment forum Australia's #1 stock forum

1PG 1-page limited

0.00%

16.5¢

Arryd and Brian replied as I would have, not to mention the...

First 8 Last

Share
Profile

Follow
TDA

11,411 Posts.

137

05/11/15

13:22

Post #: 16331676
Share

Originally posted by wadegarrett ↑

it may or may not be better, but it is the incumbent product. LinkedIN big, rich, smarter people, more of them, more coverage, lower risk, license fee as opposed to price on demand - etc etc.

Do you know how long it takes to get a new piece of software into a big complex organisation? i.e. A bank

I do. Is your product better than the incumbent?? Then risk, governance, procurement.....it goes on and on.

In addition, you have to use the product to prove its validity - so expect pilots to be small, contained and very low cost.

1PG will have to smash all of this above to stand a chance of beating LinkedIN>

Expand

Arryd and Brian replied as I would have, not to mention the 1.2bln profiles 1PG have compared to what LinkedIn has. Getting software into a bank? We have banks already and they are using the announced platforms, in the coming weeks/months many will see just how much they are using them as they roll onto stage 2 contracts.

LinkedIn have tried and would love to get their hands on 1PG's profile database!

1PG Price at posting: $4.35 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 8 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Arryd and Brian replied as I would have, not to mention the...

Top Stories

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News